Access Now: AORN COVID-19 Clinical Support

Home >  News >  December, 2015

Johnson & Johnson Hit With $12.5 Million Judgment in Mesh Case

Engineer says company never considered how to remove the mesh if it failed.

Published: December 23, 2015

MESH LAWSUIT Johnson & Johnson pulled its Prolift pelvic organ prolapse repair kit from the market in 2012.

An Indiana woman who sued Johnson & Johnson, claiming that a vaginal mesh implant made by the company caused extreme pain during sex and required numerous corrective surgeries, has been awarded $12.5 million.

A jury in Philadelphia ordered the company to pay Patricia Hammons, 65, $5.5 million in compensatory damages for ongoing health problems and inability to have sex, and tacked on an additional $7 million in punitive damages. A spokesperson says Johnson & Johnson will appeal.

The trial was one of what could end up being thousands aimed at manufacturers of pelvic mesh implants. According to the Philadelphia Inquirer, there had previously been 16 verdicts against pelvic mesh manufacturers, including J&J, totaling $247 million.

J&J began marketing its "Prolift" product in 2005, and pulled it in 2012. The company's defense may have been weakened by revelations that it knew in 2005 that pelvic mesh had been linked to dyspareunia (pain during sex), but did not include a warning on its product label.

Additionally, during Ms. Hammons's trial, a product engineer for Ethicon, the J&J subsidiary that made the mesh, said the company had never given any thought to how the mesh would be removed if it failed. The engineer said such procedures would be extremely difficult, calling the situation a surgical "train wreck."

"We believe the evidence showed Ethicon's Prolift pelvic organ prolapse repair kit was properly designed," says Matthew Johnson, director of communications for Ethicon. "Ethicon acted appropriately and responsibly in the research, development and marketing of the product, and Prolift was not the cause of the plaintiff's continuing medical problems. Studies demonstrated that Prolift was efficacious and had a low rate of post-operative complications when used with appropriate patient selection and proper surgical technique."

Jim Burger

Also in the News...

When Can Vendor Reps Return to ORs?
Coronavirus Outbreak Reignites Feud Between Anesthesia Groups
Outpatient ORs Reopening for Business
HHS Clarifies Conditions for COVID-19 Grants
CMS Issues Coronavirus Infection Control Guidance
FDA Backs Converting Anesthesia Machines to Ventilators
What's an Elective Surgery?

New to Outpatient Surgery Magazine?
Sign-up to continue reading this article.
Register Now
Have an account? Please log in:
Email Address:
  Remember my login on this computer

advertiser banner

Other Articles That May Interest You

Marijuana Users May Need Higher Doses of Sedatives Before Endoscopy

Study participants needed significantly more fentanyl, midazolam and propofol than non-users.

Jury: Orthopedic Surgeon's Routine of Performing 14 Concurrent Surgeries a Day Negligent

$2M verdict in 'assembly line' surgery case.

FDA Backs Converting Anesthesia Machines to Ventilators

The move addresses critical shortages of machines needed for COVID-19 patients.